Analysis of Amazon's entry into GLP-1

Amazon plan

Delivery

Same-day delivery from Amazon Pharmacy covers nearly 3,000 cities, expanding to 4,500 by year-end

Pricing

Injectables start at $299 a month (Wegovy, Zepbound), roughly on a par with the $299-599 a month under HIMS's Novo partnership

Summary

Amazon is launching a comprehensive GLP-1 management programme through One Medical

Telemedicine

Existing prescription holders can renew remotely 24/7: $29 for a message consultation and $49 for a video visit (renewals only, no new prescriptions)

Key insights

• Amazon sells only branded drugs, with no compounded drugs and no peptides. HIMS's differentiation lies precisely in compounded drugs and the peptide category that is about to open up, and Amazon has not touched either.
• Amazon's telemedicine handles renewals only, not first consultations for new prescriptions. HIMS's core value is a complete consultation process that starts from scratch.
• Amazon has no health-data flywheel. At HIMS, Labs blood tests, AI-personalised recommendations and cross-selling across products add up to switching costs for users, whereas Amazon is a pure distribution play.
• No pricing advantage: branded drugs at $299 a month versus Novo's own NovoCare at $149 a month, so Amazon is not cheap. If HIMS gets the qualification to offer peptides, its cost structure would be far below that of branded-drug distribution.

Price action

HIMS closed at $29.76 (-4.03%), ending a 5-day winning streak. A 4% pullback after a 49% gain in 5 days is normal digestion, and volume of 56.7 million shares was far above average.